Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180599 | 0.98 | THRB (0.71) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL3340261 | 0.98 | THRB (0.71) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL5181852 | 0.98 | THRB (0.71) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL14944646 | 0.91 | THRB (0.61) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL5179351 | 0.89 | THRB (0.57) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL5179358 | 0.89 | THRB (0.57) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL5182268 | 0.89 | THRB (0.57) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL17779599 | 0.84 | THRB (0.64) | THRBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL16352666 | 0.83 | THRB (0.55) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL11513211 | 0.83 | CYP3A4 (0.62) | THRBCYP3A4CYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389534-B2 | Pyrimidine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8349876-B2 | Pyridine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESEE RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20100069440-A1 | PYRIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2010-03-18 | — | — | US | disclosed |
| US-20100069634-A1 | PYRIMIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069634-A1 | PYRIMIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | CNR1, CNR2, GPR18 | THRB 851/4885CYP3A4 1207/4885CYP2C9 976/4885 |
| US-20100069440-A1 | PYRIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | CNR1, CNR2, NPY1R | THRB 1152/4885CYP3A4 548/4885CYP2C9 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.